is a registered trademark of Genentech, Inc.
The supplemental approval is based on data that showed longer prophylactic treatment with Valcyte
reduced the incidence of CMV disease in high risk adult kidney transplant patients from 36.
I have had to keep patients in the hospital for two or three days until the state approved their Valcyte
Pender, following his EBV-infected B cell model of autoimmunity, has had marginal success using the herpes class drugs Valcyte
, Valtrex, Acyclovir, and so on.
Roche USA, Nutley, NJ, announced the FDA has approved Valcyte
(valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients--4 months to 16 years of age--at high risk of developing CMV disease.
Tenders are invited for Medicinal Products with Valcyte
Concluding Framework Agreements
Currently, Roche's Valcyte
is the only branded drug available for the treatment of this indication.
Nutley, NJ, has received approval from the US Food and Drug Administration (FDA) for Valcyte
for the prevention of cytomegalovirus (CMV) disease in high-risk kidney, kidney-pancreas and heart transplant patients.
Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte
(valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.
MEDICATIONS: Mabthera, ROACTEMRA, Valcyte
Roche Holding AG, Basel, Switzerland, announced that the Mutual Recognition Procedure has been completed, and approved by the European Union (EU), for Valcyte
(valganciclovir) for the prevention of cytomegalovirus (CMV) disease, a potentially fatal infection that affects solid organ transplant recipients.
3 million grant from Roche Pharmaceutical, which manufactures the drug under the brand name Valcyte
, to conduct a randomized, placebo-controlled, double-blind study set to begin this quarter at Stanford.